secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001213900-25-050055
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

CERo Therapeutics enters new employment agreements with CEO and CFO effective June 4, 2025
--------------------------------------------------------------------------------

- CEO Chris Ehrlich receives base salary of $480,000/year and a one-time performance bonus of 50% of base salary.
- CFO Andrew Kucharchuk receives base salary of $300,000/year and a one-time performance bonus of 30% of base salary.
- Ehrlich receives equity awards including an option for 238,971 shares (granted March 4, 2025) and a second option for 185,529 shares.
- Kucharchuk receives an option for 152,500 shares, subject to board approval, vesting over time and performance milestones.
- The new agreements replace prior consulting agreements and convert both roles to full-time employment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/0001213900-25-050055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025050055/ea0244195-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-050055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer